DK3773737T3 - Saponin konjugeret til epitop-bindende proteiner - Google Patents

Saponin konjugeret til epitop-bindende proteiner Download PDF

Info

Publication number: DK3773737T3
Authority: DK; Denmark
Prior art keywords: epitope; binding proteins; saponin; conjugated; saponin conjugated
Prior art date: 2018-12-21

Application number

DK19835231.2T

Other languages

English (en)

Inventor

Ruben Postel

Hendrik Fuchs

Original Assignee

Sapreme Tech Bv

Univ Berlin Charite

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-21

Filing date

2019-12-09

Publication date

2021-10-04

2019-12-09 Application filed by Sapreme Tech Bv, Univ Berlin Charite filed Critical Sapreme Tech Bv

2021-10-04 Application granted granted Critical

2021-10-04 Publication of DK3773737T3 publication Critical patent/DK3773737T3/da

Links

0 C*C(C)(C)*#N Chemical compound C*C(C)(C)*#N 0.000 description 18
JEHBXJJESBILFK-UHFFFAOYSA-N C=C(C=C1)N(CCCCCC(NN)=O)C1=O Chemical compound C=C(C=C1)N(CCCCCC(NN)=O)C1=O JEHBXJJESBILFK-UHFFFAOYSA-N 0.000 description 2
JCXWNKRSLKCAJC-UHFFFAOYSA-O CCNNC(c1ccc(CCCCN(C(CC2)=O)C2=[ClH])cc1)=[NH2+] Chemical compound CCNNC(c1ccc(CCCCN(C(CC2)=O)C2=[ClH])cc1)=[NH2+] JCXWNKRSLKCAJC-UHFFFAOYSA-O 0.000 description 2
LFPODNJKHGJLRX-UHFFFAOYSA-N OCc(cc1)ccc1C(C1CC1)=O Chemical compound OCc(cc1)ccc1C(C1CC1)=O LFPODNJKHGJLRX-UHFFFAOYSA-N 0.000 description 2
MFUTZCIFSIGPOY-UHFFFAOYSA-N C=C(CC1)NC1O Chemical compound C=C(CC1)NC1O MFUTZCIFSIGPOY-UHFFFAOYSA-N 0.000 description 1
YHCKKXCUZCBAPU-UHFFFAOYSA-N CC(ON(C(CC1)O)C1=O)=O Chemical compound CC(ON(C(CC1)O)C1=O)=O YHCKKXCUZCBAPU-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
- A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Oncology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Botany (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK19835231.2T 2018-12-21 2019-12-09 Saponin konjugeret til epitop-bindende proteiner DK3773737T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
NL2022283		2018-12-21
NL2023468		2019-07-10
NL2023568		2019-07-25
PCT/EP2019/000334 WO2020126064A1 (en)	2018-12-21	2019-12-09	Saponin conjugated to epitope-binding proteins

Publications (1)

Publication Number	Publication Date
DK3773737T3 true DK3773737T3 (da)	2021-10-04

Family

ID=71101079

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK21212184.2T DK4015003T5 (da)	2018-12-21	2019-12-09	Forbedret antistof-oligonukleotid-konjugat
DK19835231.2T DK3773737T3 (da)	2018-12-21	2019-12-09	Saponin konjugeret til epitop-bindende proteiner
DK19817673.7T DK3897738T5 (da)	2018-12-21	2019-12-09	Saponin-konjugater
DK19817689.3T DK3897735T3 (da)	2018-12-21	2019-12-09	Biologisk aktiv klynge af molekyler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK21212184.2T DK4015003T5 (da)	2018-12-21	2019-12-09	Forbedret antistof-oligonukleotid-konjugat

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK19817673.7T DK3897738T5 (da)	2018-12-21	2019-12-09	Saponin-konjugater
DK19817689.3T DK3897735T3 (da)	2018-12-21	2019-12-09	Biologisk aktiv klynge af molekyler

Country Status (15)

Country	Link
US (10)	US20250195682A1 (da)
EP (16)	EP4015003B1 (da)
JP (11)	JP7541008B2 (da)
KR (9)	KR20210119979A (da)
CN (8)	CN113474009A (da)
AU (9)	AU2019411276A1 (da)
BR (2)	BR112021012222A8 (da)
CA (6)	CA3124065A1 (da)
DK (4)	DK4015003T5 (da)
ES (5)	ES3038616T3 (da)
IL (8)	IL284280A (da)
MX (2)	MX2021007296A (da)
PT (2)	PT3897735T (da)
SG (8)	SG11202106603UA (da)
WO (8)	WO2020126604A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017220751A1 (en)	2016-06-22	2017-12-28	Proqr Therapeutics Ii B.V.	Single-stranded rna-editing oligonucleotides
KR102501980B1 (ko)	2016-09-01	2023-02-20	프로큐알 테라퓨틱스 Ⅱ 비.브이.	화학적으로 변형된 단일 가닥 rna-편집 올리고뉴클레오타이드
EP3618867A4 (en)	2017-05-02	2021-01-20	Cornell University	METHODS AND REAGENTS FOR TUMOR TARGETING WITH IMPROVED EFFICIENCY AND REDUCED TOXICITY
GB201808146D0 (en)	2018-05-18	2018-07-11	Proqr Therapeutics Ii Bv	Stereospecific Linkages in RNA Editing Oligonucleotides
EP4015003B1 (en) *	2018-12-21	2023-05-10	Sapreme Technologies B.V.	Improved antibody-oligonucleotide conjugate
AU2020316679B2 (en) *	2019-07-25	2025-07-03	Sapreme Technologies B.V.	Saponin derivatives with improved therapeutic window
ES2931037T3 (es) *	2019-12-18	2022-12-23	Univ Berlin Freie	Herramienta eficiente de administración de genes con un amplio margen terapéutico
CN113527496B (zh) *	2020-04-16	2022-03-04	上海洛启生物医药技术有限公司	抗Trop2纳米抗体及其应用
EP4117730A1 (en) *	2020-06-24	2023-01-18	Sapreme Technologies B.V.	Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof
KR20230043114A (ko) *	2020-06-24	2023-03-30	사프렘 테크놀로지스 비.브이.	Galnac과 사포닌의 접합체, 상기 접합체 및 galnac-올리고뉴클레오티드 접합체를 포함하는 치료적 조성물
KR20230043112A (ko) *	2020-06-24	2023-03-30	사프렘 테크놀로지스 비.브이.	의약용 사포닌 유도체
CA3183881A1 (en) *	2020-06-24	2021-12-30	Sapreme Technologies B.V.	Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
JP7652808B2 (ja) *	2020-06-24	2025-03-27	サプリームテクノロジーズ，ベー．フェー．	Ｖｈｈを含むａｄｃ又はａｏｃと、サポニン又はリガンド－サポニンコンジュゲートとを含む組み合わせ
KR20230043115A (ko) *	2020-06-24	2023-03-30	사프렘 테크놀로지스 비.브이.	히드라존에 기반한 사포닌 유도체
JP2023532679A (ja) *	2020-06-24	2023-07-31	サプリームテクノロジーズ，ベー．フェー．	抗体－薬物コンジュゲート及び抗体－サポニンコンジュゲートの組合せ
WO2021261992A1 (en) *	2020-06-24	2021-12-30	Sapreme Technologies B.V.	Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
US20240066045A1 (en) *	2020-09-10	2024-02-29	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
WO2022055352A1 (en) *	2020-09-10	2022-03-17	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
WO2022055351A1 (en) *	2020-09-10	2022-03-17	Sapreme Technologies B.V.	Conjugate of saponin, oligonucleotide and galnac
IL301214A (en) *	2020-09-10	2023-05-01	Sapreme Tech Bv	A conjugated compound of saponin, oligonucleotide and acetylgalactosamine
US10947552B1 (en)	2020-09-30	2021-03-16	Alpine Roads, Inc.	Recombinant fusion proteins for producing milk proteins in plants
EP4222167A1 (en)	2020-09-30	2023-08-09	Nobell Foods, Inc.	Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en)	2020-09-30	2021-01-19	Alpine Roads, Inc.	Recombinant milk proteins
WO2022115625A1 (en) *	2020-11-24	2022-06-02	Brickbio, Inc.	Protein derivatives containing unnatural amino acids and branched linkers
WO2022164316A1 (en)	2021-01-26	2022-08-04	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
JP2024530839A (ja) *	2021-06-18	2024-08-26	サプリームテクノロジーズ，ベー．フェー．	サポニン、オリゴヌクレオチド、およびＧａｌＮＡｃの複合体
WO2023038517A1 (en)	2021-09-09	2023-03-16	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate
US20250295800A1 (en) *	2021-12-22	2025-09-25	Sapreme Technologies B.V.	Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
DK4452331T3 (da)	2021-12-22	2025-09-29	Sapreme Tech Bv	Målrettede saponin-nukleinsyre-konjugater til behandling af muskelsvind
JP2025500481A (ja)	2021-12-22	2025-01-09	サプリームテクノロジーズ，ベー．フェー．	筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物
IL313731A (en)	2021-12-22	2024-08-01	Sapreme Tech Bv	Preparations containing nucleic acids and sponges aimed at treating muscle wasting diseases
KR20240001074A9 (ko) *	2022-06-24	2024-11-13	주식회사 피노바이오	하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체
WO2024013360A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Oligonucleotides for adar-mediated rna editing and use thereof
WO2024046622A1 (en)	2022-09-01	2024-03-07	Sapreme Technologies B.V.	Compositions of polyplexes and saponins
EP4331609A1 (en)	2022-09-01	2024-03-06	Sapreme Technologies B.V.	Methods and compositions for enhanced polyplex delivery
EP4331610A1 (en)	2022-09-01	2024-03-06	Sapreme Technologies B.V.	Polyplex-saponin covalent conjugate
CN116259371B (zh) *	2022-09-09	2026-02-17	江苏理工学院	化合物激素受体活性预测方法和装置
EP4666071A2 (en) *	2023-02-13	2025-12-24	Nautilus Subsidiary, Inc.	Affinity reagents having artificial polymer scaffolds
CN118852442A (zh)	2023-04-26	2024-10-29	上海麦科思生物医药有限公司	抗ptk7抗体及其用途
WO2024238981A1 (en) *	2023-05-18	2024-11-21	Vycellix, Inc.	Plasma membrane embedded system for spaciotemporal controlled payload delivery of biologics
KR20260026556A (ko)	2023-06-21	2026-02-26	사프렘 테크놀로지스 비.브이.	중추신경계 장애의 치료를 위한 약제학적 조성물
WO2024261042A1 (en)	2023-06-21	2024-12-26	Sapreme Technologies B.V.	Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases
WO2025222234A1 (en) *	2024-04-24	2025-10-30	Starpharma Pty Ltd	Targeted dendrimer conjugates
EP4684805A1 (en) *	2024-07-24	2026-01-28	Universitätsmedizin der Johannes Gutenberg-Universität Mainz	Selective antibody-drug conjugates for targeted cancer therapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0058021A3 (en)	1981-02-06	1982-10-27	Beecham Group Plc	Pharmaceutical compositions
US5591829A (en) *	1987-05-29	1997-01-07	Matsushita; Shuzo	Antibodies modified with toxic substance
US5583112A (en) *	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5273965A (en)	1992-07-02	1993-12-28	Cambridge Biotech Corporation	Methods for enhancing drug delivery with modified saponins
US5856571A (en) *	1995-06-07	1999-01-05	Cellpro, Incorporated	Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
CA2290646C (en)	1997-05-20	2008-03-11	Galenica Pharmaceuticals, Inc.	Triterpene saponin analogs having adjuvant and immunostimulatory activity
WO2000009075A2 (en)	1998-08-14	2000-02-24	Galenica Pharmaceuticals, Inc.	Chemically modified saponins and the use thereof as adjuvants
US7256257B2 (en) *	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
CA2477191A1 (en) *	2002-02-04	2003-08-28	Sally Mossman	Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
US7112573B2 (en) *	2002-04-19	2006-09-26	Iowa Research, The University Foundation	Isoflavone and triterpene glycosides from soybeans
WO2004092329A2 (en)	2003-04-08	2004-10-28	Galenica Pharmaceuticals, Inc.	Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
ES2395818T3 (es) *	2004-07-13	2013-02-15	Charite - Universitatsmedizin Berlin	Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
EP1796537A4 (en)	2004-08-25	2012-03-07	Univ Michigan	DENDRIMER BASED COMPOSITIONS AND METHOD FOR THEIR USE
WO2007059782A1 (en)	2005-11-28	2007-05-31	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
DK2094278T3 (da) *	2006-11-20	2017-07-24	Duecom	Anvendelse af lipidindholdende partikler, omfattende quillaja saponins til behandling af cancer
WO2008109105A2 (en) *	2007-03-06	2008-09-12	Flagship Ventures	Methods and compositions for improved therapeutic effects with sirna
CA2719555A1 (en) *	2008-03-26	2009-10-01	National Research Council Of Canada	Saponin extract from saponaria spp. and uses thereof
ES2710463T3 (es) *	2008-04-11	2019-04-25	Cedars Sinai Medical Center	Acido poli(beta málico) con tripéptido colgante Leu-Leu-Leu para la administración eficaz del fármaco citoplasmático
WO2011054811A1 (en) *	2009-11-03	2011-05-12	Santaris Pharma A/S	Rna antagonists targeting hsp27 combination therapy
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9125835B2 (en) *	2010-11-12	2015-09-08	Rutgers, The State University Of New Jersey	Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
CN102652836A (zh) *	2011-03-03	2012-09-05	华中科技大学同济医学院附属协和医院	靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
JP2015505850A (ja) *	2011-12-14	2015-02-26	シアトルジェネティックス，インコーポレイテッド	新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
WO2014082065A1 (en) *	2012-11-26	2014-05-30	President And Fellows Of Harvard College	Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
US9907846B2 (en)	2013-04-01	2018-03-06	Mx Adjuvac Ab	Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
GB201400994D0 (en) *	2014-01-21	2014-03-05	Ucl Business Plc	Drug delivery system
US10744204B2 (en)	2014-04-11	2020-08-18	Medimmune, Llc	Conjugated compounds comprising cysteine-engineered antibodies
EP3929202A1 (en)	2014-05-30	2021-12-29	Memorial Sloan-Kettering Cancer Center	Minimal saponin analogues, synthesis and use thereof
TW201617368A (zh) *	2014-09-05	2016-05-16	史坦森特瑞斯公司	新穎抗ｍｆｉ２抗體及使用方法
CN106892957B (zh) *	2015-12-17	2018-11-16	广州中医药大学	一种齐墩果烷型三萜皂苷类化合物及其制备方法和应用
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
ES3009750T3 (en)	2016-09-26	2025-03-31	Desert King Chile S A	Production of biomass in ultra high density plantations
WO2019011914A1 (en)	2017-07-11	2019-01-17	Freie Universität Berlin	NOVEL USES OF SAPONIN AND METHOD FOR ITS ISOLATION
EP4015003B1 (en)	2018-12-21	2023-05-10	Sapreme Technologies B.V.	Improved antibody-oligonucleotide conjugate
AU2020316679B2 (en)	2019-07-25	2025-07-03	Sapreme Technologies B.V.	Saponin derivatives with improved therapeutic window
WO2022055352A1 (en) *	2020-09-10	2022-03-17	Sapreme Technologies B.V.	Semicarbazone-based saponin conjugate

2019
- 2019-12-09 EP EP21212184.2A patent/EP4015003B1/en active Active
- 2019-12-09 MX MX2021007296A patent/MX2021007296A/es unknown
- 2019-12-09 WO PCT/EP2019/084190 patent/WO2020126604A1/en not_active Ceased
- 2019-12-09 CN CN201980092858.6A patent/CN113474009A/zh active Pending
- 2019-12-09 WO PCT/EP2019/000334 patent/WO2020126064A1/en not_active Ceased
- 2019-12-09 WO PCT/EP2019/084290 patent/WO2020126626A1/en not_active Ceased
- 2019-12-09 BR BR112021012222A patent/BR112021012222A8/pt not_active Application Discontinuation
- 2019-12-09 JP JP2021536411A patent/JP7541008B2/ja active Active
- 2019-12-09 CA CA3124065A patent/CA3124065A1/en active Pending
- 2019-12-09 SG SG11202106603UA patent/SG11202106603UA/en unknown
- 2019-12-09 PT PT198176893T patent/PT3897735T/pt unknown
- 2019-12-09 WO PCT/EP2019/084210 patent/WO2020126609A2/en not_active Ceased
- 2019-12-09 WO PCT/EP2019/084211 patent/WO2020126610A1/en not_active Ceased
- 2019-12-09 US US17/413,965 patent/US20250195682A1/en active Pending
- 2019-12-09 KR KR1020217023069A patent/KR20210119979A/ko not_active Ceased
- 2019-12-09 ES ES23170913T patent/ES3038616T3/es active Active
- 2019-12-09 US US17/312,193 patent/US20220054643A1/en active Pending
- 2019-12-09 US US17/312,403 patent/US20220111066A1/en not_active Abandoned
- 2019-12-09 EP EP19820708.6A patent/EP3897741A1/en active Pending
- 2019-12-09 JP JP2021536414A patent/JP7593925B2/ja active Active
- 2019-12-09 CA CA3124406A patent/CA3124406A1/en active Pending
- 2019-12-09 SG SG11202106672SA patent/SG11202106672SA/en unknown
- 2019-12-09 EP EP19817677.8A patent/EP3897739B1/en active Active
- 2019-12-09 EP EP25172979.4A patent/EP4588523A3/en active Pending
- 2019-12-09 SG SG11202106572QA patent/SG11202106572QA/en unknown
- 2019-12-09 AU AU2019411276A patent/AU2019411276A1/en active Pending
- 2019-12-09 CA CA3123978A patent/CA3123978A1/en active Pending
- 2019-12-09 SG SG11202106612QA patent/SG11202106612QA/en unknown
- 2019-12-09 EP EP19817689.3A patent/EP3897735B1/en active Active
- 2019-12-09 US US17/312,476 patent/US20220072149A1/en active Pending
- 2019-12-09 EP EP19817672.9A patent/EP3897743A1/en active Pending
- 2019-12-09 AU AU2019400630A patent/AU2019400630B2/en active Active
- 2019-12-09 ES ES21212184T patent/ES2952017T3/es active Active
- 2019-12-09 SG SG11202106664PA patent/SG11202106664PA/en unknown
- 2019-12-09 AU AU2019408811A patent/AU2019408811A1/en active Pending
- 2019-12-09 JP JP2021536413A patent/JP7654546B2/ja active Active
- 2019-12-09 PT PT212121842T patent/PT4015003T/pt unknown
- 2019-12-09 CN CN201980092610.XA patent/CN113498350A/zh active Pending
- 2019-12-09 CN CN202510019306.XA patent/CN119950740A/zh active Pending
- 2019-12-09 EP EP19817682.8A patent/EP3856254A2/en active Pending
- 2019-12-09 KR KR1020217022975A patent/KR20210110323A/ko active Pending
- 2019-12-09 US US17/312,104 patent/US20220023433A1/en active Pending
- 2019-12-09 JP JP2021536410A patent/JP7502301B2/ja active Active
- 2019-12-09 EP EP19817676.0A patent/EP3897742A2/en active Pending
- 2019-12-09 CA CA3124129A patent/CA3124129A1/en active Pending
- 2019-12-09 JP JP2021536412A patent/JP7614094B2/ja active Active
- 2019-12-09 SG SG11202106574UA patent/SG11202106574UA/en unknown
- 2019-12-09 EP EP20209450.4A patent/EP3808379A1/en active Pending
- 2019-12-09 EP EP19817673.7A patent/EP3897738B1/en active Active
- 2019-12-09 MX MX2021007449A patent/MX2021007449A/es unknown
- 2019-12-09 ES ES19817689T patent/ES3059876T3/es active Active
- 2019-12-09 KR KR1020217023071A patent/KR20210117274A/ko not_active Ceased
- 2019-12-09 ES ES19835231T patent/ES2899612T3/es active Active
- 2019-12-09 EP EP25203109.1A patent/EP4647436A3/en active Pending
- 2019-12-09 ES ES19817677T patent/ES2985240T3/es active Active
- 2019-12-09 KR KR1020257035339A patent/KR20250160210A/ko active Pending
- 2019-12-09 CN CN201980092709.XA patent/CN113507941A/zh active Pending
- 2019-12-09 WO PCT/EP2019/084180 patent/WO2020126600A1/en not_active Ceased
- 2019-12-09 CN CN201980092811.XA patent/CN113474010A/zh active Pending
- 2019-12-09 US US17/312,311 patent/US20230173085A1/en not_active Abandoned
- 2019-12-09 AU AU2019411289A patent/AU2019411289B2/en active Active
- 2019-12-09 KR KR1020217023032A patent/KR102894465B1/ko active Active
- 2019-12-09 JP JP2021536407A patent/JP7652695B2/ja active Active
- 2019-12-09 KR KR1020217023063A patent/KR20210119978A/ko not_active Ceased
- 2019-12-09 DK DK21212184.2T patent/DK4015003T5/da active
- 2019-12-09 SG SG11202106575YA patent/SG11202106575YA/en unknown
- 2019-12-09 CA CA3124151A patent/CA3124151A1/en active Pending
- 2019-12-09 CN CN201980092673.5A patent/CN113747923A/zh active Pending
- 2019-12-09 US US17/415,759 patent/US20220218837A1/en active Pending
- 2019-12-09 DK DK19835231.2T patent/DK3773737T3/da active
- 2019-12-09 KR KR1020217023075A patent/KR20210107073A/ko active Pending
- 2019-12-09 KR KR1020217023076A patent/KR20210117276A/ko active Pending
- 2019-12-09 AU AU2019407234A patent/AU2019407234B2/en active Active
- 2019-12-09 US US17/312,019 patent/US12453782B2/en active Active
- 2019-12-09 EP EP23166479.8A patent/EP4223316A3/en active Pending
- 2019-12-09 CN CN201980092771.9A patent/CN113453722A/zh active Pending
- 2019-12-09 WO PCT/EP2019/084292 patent/WO2020126627A1/en not_active Ceased
- 2019-12-09 SG SG11202106606RA patent/SG11202106606RA/en unknown
- 2019-12-09 EP EP19835231.2A patent/EP3773737B1/en active Active
- 2019-12-09 AU AU2019411278A patent/AU2019411278B2/en active Active
- 2019-12-09 BR BR112021012225A patent/BR112021012225A8/pt not_active IP Right Cessation
- 2019-12-09 WO PCT/EP2019/084242 patent/WO2020126620A2/en not_active Ceased
- 2019-12-09 CA CA3124064A patent/CA3124064A1/en active Pending
- 2019-12-09 CN CN202510084422.XA patent/CN119868574A/zh active Pending
- 2019-12-09 EP EP21186481.4A patent/EP3915587B1/en active Active
- 2019-12-09 DK DK19817673.7T patent/DK3897738T5/da active
- 2019-12-09 DK DK19817689.3T patent/DK3897735T3/da active
- 2019-12-09 EP EP23170913.0A patent/EP4241847B1/en active Active
- 2019-12-09 KR KR1020217023074A patent/KR20210117275A/ko active Pending
- 2019-12-09 EP EP24169240.9A patent/EP4374927A3/en active Pending
2021
- 2021-06-21 IL IL284280A patent/IL284280A/en unknown
- 2021-06-21 IL IL284272A patent/IL284272A/en unknown
- 2021-06-21 IL IL284273A patent/IL284273A/en unknown
- 2021-06-21 IL IL284274A patent/IL284274A/en unknown
- 2021-06-21 IL IL284265A patent/IL284265A/en unknown
- 2021-06-21 IL IL284279A patent/IL284279A/en unknown
- 2021-06-21 IL IL284278A patent/IL284278A/en unknown
- 2021-06-21 IL IL284276A patent/IL284276A/en unknown
2024
- 2024-11-15 JP JP2024199932A patent/JP2025015702A/ja active Pending
- 2024-12-16 US US18/981,715 patent/US20250302983A1/en active Pending
- 2024-12-26 JP JP2024230339A patent/JP2025041928A/ja active Pending
2025
- 2025-02-04 US US19/044,661 patent/US20260000783A1/en active Pending
- 2025-03-13 JP JP2025040440A patent/JP2025090776A/ja active Pending
- 2025-03-19 JP JP2025046058A patent/JP2025094140A/ja active Pending
- 2025-03-19 JP JP2025046059A patent/JP2025102831A/ja active Pending
- 2025-03-28 AU AU2025202242A patent/AU2025202242A1/en active Pending
- 2025-04-29 AU AU2025203017A patent/AU2025203017A1/en active Pending
- 2025-04-30 AU AU2025203092A patent/AU2025203092A1/en active Pending

Also Published As

Publication number	Publication date
JP7652695B2 (ja)	2025-03-27
CN119950740A (zh)	2025-05-09
KR20210107073A (ko)	2021-08-31
EP3897738A1 (en)	2021-10-27
AU2019407234A2 (en)	2021-08-26
CN113474010A (zh)	2021-10-01
CA3123978A1 (en)	2020-06-25
US20250302983A1 (en)	2025-10-02
IL284278A (en)	2021-08-31
CA3124129A1 (en)	2020-06-25
EP3856254A2 (en)	2021-08-04
JP2025102831A (ja)	2025-07-08
DK4015003T3 (da)	2023-06-12
JP2025041928A (ja)	2025-03-26
EP3897739B1 (en)	2024-04-17
ES2985240T3 (es)	2024-11-04
SG11202106672SA (en)	2021-07-29
EP4241847A3 (en)	2023-10-04
IL284279A (en)	2021-08-31
EP3897735A1 (en)	2021-10-27
CN113747923A (zh)	2021-12-03
EP4647436A3 (en)	2026-02-25
KR20210119979A (ko)	2021-10-06
US20220054643A1 (en)	2022-02-24
AU2025202242A1 (en)	2025-04-17
SG11202106603UA (en)	2021-07-29
SG11202106574UA (en)	2021-07-29
DK3897738T5 (da)	2024-08-05
EP3897741A1 (en)	2021-10-27
IL284280A (en)	2021-08-31
JP2022516044A (ja)	2022-02-24
CN113474009A (zh)	2021-10-01
WO2020126626A1 (en)	2020-06-25
DK3897738T3 (da)	2024-02-19
AU2019408811A1 (en)	2021-08-12
KR20210117276A (ko)	2021-09-28
EP3808379A1 (en)	2021-04-21
CN113498350A (zh)	2021-10-12
KR20250160210A (ko)	2025-11-11
EP4223316A3 (en)	2023-10-04
EP4374927A3 (en)	2024-08-21
SG11202106664PA (en)	2021-07-29
JP2022516045A (ja)	2022-02-24
AU2019407234A1 (en)	2021-08-19
JP2025015702A (ja)	2025-01-30
AU2019411278B2 (en)	2025-02-20
US20220072149A1 (en)	2022-03-10
EP3897735B1 (en)	2025-10-22
KR20210110323A (ko)	2021-09-07
EP4647436A2 (en)	2025-11-12
AU2019408811A2 (en)	2021-09-02
SG11202106612QA (en)	2021-07-29
EP3897739C0 (en)	2024-04-17
JP2022515797A (ja)	2022-02-22
JP2022516043A (ja)	2022-02-24
AU2019407234B2 (en)	2025-03-13
ES3038616T3 (en)	2025-10-14
BR112021012222A2 (da)	2021-11-30
EP3915587B1 (en)	2026-03-25
EP3897739A1 (en)	2021-10-27
EP4241847A2 (en)	2023-09-13
WO2020126609A2 (en)	2020-06-25
CA3124151A1 (en)	2020-06-25
MX2021007449A (es)	2021-12-10
US20220023433A1 (en)	2022-01-27
EP4588523A3 (en)	2025-11-12
EP3897743A1 (en)	2021-10-27
IL284276A (en)	2021-08-31
EP3773737B1 (en)	2021-09-01
US20220218837A1 (en)	2022-07-14
JP7502301B2 (ja)	2024-06-18
JP2022515251A (ja)	2022-02-17
IL284265A (en)	2021-08-31
AU2025203017A9 (en)	2026-03-05
EP3897742A2 (en)	2021-10-27
EP4223316A2 (en)	2023-08-09
ES2952017T3 (es)	2023-10-26
WO2020126620A2 (en)	2020-06-25
KR20210117275A (ko)	2021-09-28
EP3773737A1 (en)	2021-02-17
EP4374927A2 (en)	2024-05-29
US20250195682A1 (en)	2025-06-19
KR20210119978A (ko)	2021-10-06
CA3124065A1 (en)	2020-06-25
CN113507941A (zh)	2021-10-15
EP4241847C0 (en)	2025-06-04
US20230173085A1 (en)	2023-06-08
JP7593925B2 (ja)	2024-12-03
WO2020126620A3 (en)	2020-07-23
ES3059876T3 (en)	2026-03-24
JP7541008B2 (ja)	2024-08-27
IL284274A (en)	2021-08-31
AU2025203092A1 (en)	2025-05-22
JP2025094140A (ja)	2025-06-24
EP3897738B1 (en)	2024-01-24
IL284273A (en)	2021-08-31
WO2020126604A1 (en)	2020-06-25
AU2019411289A2 (en)	2021-08-26
WO2020126064A1 (en)	2020-06-25
AU2025203092A9 (en)	2026-03-05
CA3124406A1 (en)	2020-06-25
NZ778372A (en)	2025-03-28
CN113453722A (zh)	2021-09-28
SG11202106572QA (en)	2021-07-29
EP4241847B1 (en)	2025-06-04
KR102894465B1 (ko)	2025-12-05
SG11202106606RA (en)	2021-07-29
KR20210117274A (ko)	2021-09-28
WO2020126609A3 (en)	2020-08-13
CA3124064A1 (en)	2020-06-25
JP7654546B2 (ja)	2025-04-01
US20220313834A1 (en)	2022-10-06
BR112021012225A2 (da)	2021-11-30
US20260000783A1 (en)	2026-01-01
EP3915587A1 (en)	2021-12-01
KR20210119976A (ko)	2021-10-06
SG11202106575YA (en)	2021-07-29
WO2020126600A1 (en)	2020-06-25
AU2025203017A1 (en)	2025-05-22
BR112021012225A8 (pt)	2023-04-25
WO2020126610A1 (en)	2020-06-25
AU2019400630B2 (en)	2025-03-27
PT3897735T (pt)	2026-01-16
AU2019400630A1 (en)	2021-08-12
AU2019400630A2 (en)	2021-08-26
IL284272A (en)	2021-08-31
EP4015003A1 (en)	2022-06-22
EP4588523A2 (en)	2025-07-23
DK4015003T5 (da)	2024-08-05
DK3897735T3 (da)	2025-11-03
AU2019411289A1 (en)	2021-08-12
WO2020126627A1 (en)	2020-06-25
PT4015003T (pt)	2023-07-17
JP2022515250A (ja)	2022-02-17
EP4015003B1 (en)	2023-05-10
ES2899612T3 (es)	2022-03-14
AU2019411276A1 (en)	2021-08-12
WO2020126610A9 (en)	2020-09-24
US12453782B2 (en)	2025-10-28
US20220111066A1 (en)	2022-04-14
JP7614094B2 (ja)	2025-01-15
AU2019411289B2 (en)	2025-08-14
BR112021012222A8 (pt)	2023-04-25
CN119868574A (zh)	2025-04-25
MX2021007296A (es)	2021-12-10
JP2025090776A (ja)	2025-06-17
AU2019411278A1 (en)	2021-08-12

Publication	Publication Date	Title
DK3773737T3 (da)	2021-10-04	Saponin konjugeret til epitop-bindende proteiner
FR24C1056I2 (fr)	2025-10-17	Nouveaux anticorps anti-pd-l1
IL267797B1 (en)	2023-03-01	Anti-gpc3 antibody
IL268920A (en)	2019-10-31	Peptide vaccines
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
EP3589313A4 (en)	2021-05-19	ANTI-TIGITE ANTIBODY
LT3723783T (lt)	2023-03-27	Į mitochondrijas nukreipiami peptidai
EP3307777A4 (en)	2019-02-13	NOVEL ANTI-PD-L1 ANTIBODIES
EP3684806A4 (en)	2021-09-22	NEW ANTI-CD3EPSILON ANTIBODIES
IL270182B (en)	2022-06-01	Triterpene saponin analogues
DK3479138T3 (da)	2026-02-23	Hyperspektral sonar
DK3784047T3 (da)	2024-10-07	Gærproteiner
EP3617231A4 (en)	2021-04-07	ANTI-GPC-1 ANTIBODY
EP3596126A4 (en)	2021-03-03	NOVEL ANTI-TRKB ANTIBODIES
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP3606963C0 (en)	2023-08-30	ANTIBODIES BINDING TO STEAP-1
EP3355931C0 (en)	2024-06-26	PROTEIN CONJUGATES
LT3375889T (lt)	2020-06-25	Vienos ląstelės analizė
IL272266A (en)	2020-03-31	Anti-cd147 antibody
PL3655420T3 (pl)	2026-02-16	Chromatografia
MA51135A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
IL280533A (en)	2021-03-01	Topical composition
IT201700036862A1 (it)	2018-10-04	Hangar migliorato
EP3802565A4 (en)	2022-09-14	POLYPEPTIDES
EP3595691A4 (en)	2020-11-25	PLANT-BASED COMPOSITION